

Why does tumor necrosis factor targeted therapy reactivate tuberculosis?

Stefan Ehlers

J Rheumatol 2005;74;35-39

<http://www.jrheum.org/content/74/35>

1. Sign up for TOCs and other alerts
<http://www.jrheum.org/alerts>
2. Information on Subscriptions
<http://jrheum.com/faq>
3. Information on permissions/orders of reprints
http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.

Why Does Tumor Necrosis Factor Targeted Therapy Reactivate Tuberculosis?

STEFAN EHLERS

ABSTRACT. Treatment of chronic inflammatory conditions, such as rheumatoid arthritis and Crohn's disease, with tumor necrosis factor (TNF) targeted biologics is associated with an increased risk of infectious complications, especially tuberculosis (TB). Clinical studies have revealed that monoclonal anti-TNF antibodies (e.g., infliximab) more frequently reactivate TB than a TNF receptor p75 immunoglobulin fusion construct (etanercept). Experimental studies in mice have shown TNF to be an essential component of protective granuloma formation. Based on these studies and the known pharmacological properties of the 2 prototype TNF targeted biologic agents, this review discusses 3 hypotheses that might explain the unpredicted differential risk of infectious complications: differential induction of target cell death, differential TNF receptor signaling, and differential net inhibition of TNF bioavailability. (J Rheumatol 2005;32 Suppl 74:35-39)

Key Indexing Terms:

TUMOR NECROSIS FACTOR
APOPTOSIS

RHEUMATOID ARTHRITIS

TUBERCULOSIS
CROHN'S DISEASE

INTRODUCTION

A number of recent reports have drawn attention to infectious complications associated with the use of tumor necrosis factor (TNF) targeted biological therapies^{1,2}. In particular, increased reports of reactivation tuberculosis (TB) are of concern^{3,4}. Although it is almost impossible to directly compare complication rates in the different clinical trials, there is substantial evidence that treatment with anti-TNF antibodies (e.g., infliximab) bears an increased risk of 5 to 10-fold of reactivating TB, compared to other treatments in the respective study populations^{5,6}. In contrast, treatment with a TNF receptor p75 immunoglobulin fusion construct (etanercept) does not appear to lead to a higher incidence of TB⁷. Since both reagent classes share the same therapeutic target (neutralization of TNF activity), it is intriguing to speculate that they must differ in some other mode of action that might explain this differential frequency of infectious complications.

TNF AND TNF TARGETED BIOLOGICS

TNF is a multipotent cytokine that occurs in a soluble

From the Molecular Infection Biology Research Center Borstel, Leibniz Center for Medicine and Biosciences, Borstel, Germany.

Supported by grants from the Deutsche Forschungsgemeinschaft (SFB367-C9, SFB415-C7, SFB470-C9, GRK288-A3) and the Focus on Defence against Infection (University of Lübeck C3).

Dr. Ehlers has presented data from his own publicly funded research on the role of TNF and lymphotoxin in experimental tuberculosis at several international symposia sponsored by Angen.

S. Ehlers, MD.

Address reprint requests to Dr. S. Ehlers, Molecular Infection Biology Research Center Borstel, Leibniz Center for Medicine and Biosciences, Parkallee 22, D-23845 Borstel, Germany. E-mail: sehlers@fz-borstel.de

and transmembrane form. The soluble form binds to both TNF receptors (p55 and p75), whereas the transmembrane form predominantly signals via TNFRp75⁸. Infliximab is a chimeric anti-TNF monoclonal antibody with murine variable regions and human IgG1 constant regions that binds soluble TNF and transmembrane TNF⁹. Infliximab needs to be administered intravenously every 2 weeks. Diseases for which infliximab is effective include Crohn's (CD), psoriasis, sarcoidosis, rheumatoid arthritis (RA), and the spondyloarthropathies (SpA). Etanercept is a dimeric fusion protein consisting of the extracellular portion of the human p75 TNF receptor linked to the Fc domains of human IgG1 that antagonizes soluble TNF but interacts with transmembrane TNF with reduced avidity compared to infliximab⁹. Etanercept is administered subcutaneously twice weekly. It is therapeutically effective in RA and SpA, but not in CD or sarcoidosis.

COMMON MODE OF ACTION: NEUTRALIZING TNF ACTION

Granuloma formation is the hallmark of mycobacterial infections and represents an effort by the host to contain persisting viable microorganisms (Figure 1)¹⁰. Following ingestion of *Mycobacterium tuberculosis* in alveolar macrophages, TNF, among other proinflammatory cytokines, triggers a steady influx of granulocytes and monocytes into the alveolar and interstitial spaces¹¹. TNF is necessary to fully mature dendritic cells for antigen-presentation in the local lymph node and thus primes and amplifies the specific T cell response¹². Recruitment of monocytes and circulating antigen-specific T cells into the site of infection is made possible by TNF action on the vascular endothelium (e.g., induction of adhesion molecules such as ICAM-1) and the capacity of TNF to

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2005. All rights reserved.

Ehlers: TNF, anti-TNF, and TB

35




Figure 1. TNF acts at multiple steps in protective granuloma formation in response to *M. tuberculosis* infection. A. TNF derived from infected alveolar macrophages initially induces recruitment of a mixed cellular alveolar and interstitial infiltrate. B. Under the influence of TNF and T cell derived IFN- γ , mononuclear cells accumulate to form a highly structured granuloma. Here, TNF and IFN- γ activate mycobactericidal pathways within macrophages and regulate excessive inflammation by inducing apoptosis of T cells. C. Macrophage and T cell derived TNF is necessary to continuously orchestrate the recruitment of mononuclear cells into granulomas in order to maintain effective containment of mycobacterial foci of infection.

establish chemokine gradients [e.g., for chemokine CC motif ligand 2 (CCL2), CCL3, CCL5]^{13,14}. Effector T cells then produce both TNF and interferon- γ (IFN- γ) within the lesion to drive the macrophage enzymatic machinery that elaborates reactive oxygen and nitrogen intermediates with potent antimicrobial activity^{15,16}. TNF and IFN- γ induce further adhesion molecules necessary for ordered juxtaposition of T cells and macrophages within the granuloma that allows for other, contact-dependent modes of mycobactericidal action (e.g., perforin-mediated granulysin extrusion)^{17,18}. Both TNF and IFN- γ are potent inducers of apoptosis^{19,20}. While this action somewhat limits the overall extent of the inflammatory response, continued recruitment of cells is necessary to offset the loss of apoptotic cells and to maintain granuloma structure. It is particularly important during the chronic phase of infection in order to prevent reactivation of disease, since some mycobacteria remain viable within granuloma macrophages.

Mouse studies have convincingly shown that the presence of TNF and TNFRp55 signaling is a prerequisite for adequate host defense against *M. tuberculosis*, *Histoplasma capsulatum*, *Listeria monocytogenes*, and other granulomatous infections²¹⁻²⁴. For mycobacterial infections in particular, there is ample evidence from the mouse model that the absence of TNF or TNFRp55 results in exacerbated bacterial loads, inefficient granuloma formation, and accelerated death of experimentally

infected animals^{21,25,26}. Moreover, neutralization of TNF during chronic latent tuberculosis is followed by resumption of bacterial replication within granulomatous lesions²⁷⁻²⁹.

Neutralization and binding studies with exogenously added TNF *in vitro* have demonstrated that both infliximab and etanercept efficiently block TNF bioactivity^{9,30}. In terms of infectious complications, one would therefore predict that all TNF targeted biologicals should adversely affect the risk of infection, particularly with intracellularly viable microorganisms that require granuloma formation for their containment.

DIFFERENTIAL MODE OF ACTION: 3 HYPOTHESES

Why then would some TNF-neutralizing agents be more fraught with infectious complications than others? Three hypotheses may be considered that involve differential modes of action of the 2 classes of TNF targeted biologics, monoclonal antibodies and soluble TNF receptor constructs (Figure 2).

TNF signaling. Infliximab binds both soluble and transmembrane TNF, whereas etanercept has a 4-fold lower binding affinity for transmembrane TNF⁹. This implies that infliximab inhibits both TNFRp55 and TNFRp75 mediated events, whereas etanercept may leave TNFRp75 mediated signaling at least partially intact. Studies in murine models of inflammatory and autoimmune disorders have highlighted that TNFRp55 signaling is predominantly associated with the proinflammatory tissue-damaging sequelae of TNF action, whereas TNFRp75 signaling mostly supports immunoregulatory functions and may, indeed, suppress inflammatory events³¹.

In the mouse model of *L. monocytogenes* infection, the death domain of the TNFRp55 was unequivocally shown to be the essential signal-transducing component for initiating bactericidal pathways^{32,33}, whereas mice lacking the TNFRp75 behaved identically to wild-type mice³⁴. Evidence is only now accumulating in infection models with *M. tuberculosis* that mice with only the transmembrane form of TNF are still relatively resistant against mycobacterial challenge infections³⁵. This would argue that transmembrane signaling via TNFRp75, possibly preserved during the use of etanercept, may provide sufficient residual protective immunity against TB to prevent reactivation, at least under certain experimental conditions.

Net neutralization. Infliximab binds TNF in a fast and irreversible fashion *in vitro*. In contrast, etanercept has both high on- and high off-binding kinetics, shedding about 50% of soluble TNF and 90% of transmembrane TNF only 10 minutes after binding⁹. Once bound to infliximab, TNF is therefore completely neutralized, whereas TNF bound to etanercept may be shed in a bioavailable form at sites of




Figure 2. Differential modes of action of infliximab and etanercept. A. Soluble TNF (small rectangles, released from cell membrane at the bottom) preferentially binds to TNF-Rp55 (dark trimeric tubes on top of cell membrane), transmembrane TNF (large rectangles) predominantly binds to TNF-Rp75 (light trimeric tubes). B. Etanercept preferentially neutralizes soluble TNF, leaving TNF-Rp75 signaling largely intact. C. Infliximab neutralizes both soluble and transmembrane TNF forms. D. Infliximab binds to transmembrane TNF and via complement or antibody-dependent cellular cytotoxicity (*) initiates lysis of target cells. Alternatively, infliximab induces reverse signaling in transmembrane TNF-bearing cells, causing apoptosis.

lower concentration. In the context of TB, this would imply that infliximab disrupts granuloma integrity, because 100% neutralization of TNF will invariably result in a severely diminished inflammatory cell recruitment, so that the high turnover of cells within the dynamic granuloma can no longer be maintained. Also, 100% blockade will substantially decrease macrophage activation, causing *M. tuberculosis* organisms to regrow within the granuloma. Etanercept, on the other hand, could be envisioned to partially preserve granuloma integrity because it would allow redistribution of bioactive TNF from sites of production, such as the rheumatoid joint, into other tissues where overall TNF concentrations are low. TNF bioactivity therefore may not be entirely blocked, preserving residual antimicrobial functions of the macrophage in granulomatous lesions.

There are no data on the actual amount of TNF that causes tissue-damaging inflammation and pain in the context of RA. Similarly, there are no *in vivo* data on the minimal amount of TNF required in the context of intracellular infections to provide sufficient macrophage activation and granuloma maintenance. Hypothetically, 70-90% blockade of TNF bioactivity might leave sufficient antimicrobial effector mechanisms intact to prevent reactivation of latent TB, while still adequately relieving disease symptoms in RA.

Target cell death. Monoclonal antibodies such as infliximab — after binding to membrane-anchored TNF on monocytes or lymphocytes — are known to activate complement or cause antibody-dependent cellular cytotoxicity via their Fc tails³⁶. In the context of TB, lysed granuloma macrophages would release mycobacteria into the bloodstream, providing a possible explanation for the relatively high occurrence of disseminated TB in infliximab-treated patients. However, no studies have directly demonstrated target cell lysis by infliximab.

Infliximab has been shown to cause apoptosis in monocytes and lamina propria T cells from patients with CD^{30,37}. It is possible that elimination of effector T cells represents an additional mode of action for anti-TNF antibodies, explaining why they provide superior efficacy in CD over etanercept. If T cells with specific reactivity against mycobacterial antigens express transmembrane TNF, and if anti-TNF antibodies cause the elimination of these memory cells by inducing apoptosis, reactivation TB in infliximab treated patients might tentatively be the consequence of the loss of specifically reactive, IFN- γ -producing and macrophage-activating T cells. This hypothesis, however, has not been formally confirmed. Indeed, analyses from tissue biopsies following anti-TNF treatment in humans and mice are conflicting: apoptosis was found to be increased in *M. tuberculosis* infected mice treated with anti-TNF²⁷, but was apparently reduced in granulomas following infliximab treatment in patients³.

The relative importance of apoptosis in the defense against *M. tuberculosis* infection is controversial. *In vitro* studies demonstrating that highly virulent mycobacterial strains can evade apoptosis in alveolar macrophages have argued that this may represent an effective evasion mechanism on the part of the mycobacterium^{38,39}. In addition, some studies show decreased viability of mycobacteria in apoptotic cells^{40,41}, particularly if induction of apoptosis is accompanied by the presence of granulysin or other mycobactericidal peptides^{17,42}, but others have failed to confirm this finding⁴³. Indeed, as long as mycobacteria are not effectively killed by the apoptotic machinery, the uptake of apoptotic cells by bystander macrophages is a process that causes little inflammation and may be thought of as a Trojan horse mode of “silent entry.” In corroboration of the latter view, there is a lot of macrophage apoptosis even in TNFRp55-deficient mice without any beneficial effect on mycobacterial killing²⁶.

The relative importance of any apoptosis-promoting properties of anti-TNF antibodies remains to be determined in further studies. Etanercept has not been reported to have apoptosis-inducing activity.

CONCLUSION

The differential risk profile of the 2 most commonly used TNF targeted biologicals, infliximab and etanercept, have highlighted the gaps in our understanding of how they truly work *in vivo*. With respect to TB, animal models are available that can help identify which hypothesis concerning the mode of action is most likely to explain the differential efficacy and safety profile. It is to be hoped that from this renewed alliance of clinical and basic research efforts a new generation of TNF targeted drugs may be developed that minimize the risk of infection while preserving their antiinflammatory potency.

ACKNOWLEDGMENT

The figures were designed by I. Bouchain.

REFERENCES

1. Fleischmann R. Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid arthritis and juvenile rheumatoid arthritis. *Expert Opin Drug Saf* 2003;2:347-65.
2. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. *J Rheumatol* 2002;29 Suppl 65:33-8.
3. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med* 2001;345:1098-104.
4. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. *Lancet Infect Dis* 2003;3:148-55.
5. Wallis RS, Broder MS, Wong JY, Hanson JY, Beenhouwer DO. Granulomatous infectious diseases associated with TNF antagonists. *Clin Infect Dis* 2004;38:1261-5.
6. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. *Arthritis Rheum* 2003;48:2122-7.
7. Fleischmann R, Iqbal I, Nandeshwar P, Quiceno A. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. *Drug Saf* 2002;25:173-97.
8. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. *Cell* 1995;83:793-802.
9. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. *J Pharmacol Exp Ther* 2002;301:418-26.
10. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. *Immunol Cell Biol* 2000;78:334-41.
11. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. *Cytokine Growth Factor Rev* 2003;14:185-91.
12. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. *Cell* 2001;106:255-8.
13. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. *J Immunol* 2002;168:4620-7.
14. Mulligan MS, Vaporciyan AA, Miyasaka M, Tamatani T, Ward PA. Tumor necrosis factor alpha regulates *in vivo* intrapulmonary expression of ICAM-1. *Am J Pathol* 1993;142:1739-49.
15. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. *Annu Rev Immunol* 1997;15:323-50.
16. Flynn JL, Chan J. Immunology of tuberculosis. *Annu Rev Immunol* 2001;19:93-129.
17. Stenger S, Rosat JP, Bloom BR, Krensky AM, Modlin RL. Granulysin: a lethal weapon of cytolytic T cells. *Immunol Today* 1999;20:390-4.
18. Sousa AO, Mazzaccaro RJ, Russell RG, et al. Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice. *Proc Natl Acad Sci USA* 2000;97:4204-8.
19. Thorburn A. Death receptor-induced cell killing. *Cell Signal* 2004;16:139-44.
20. Dalton DK, Haynes L, Chu CQ, Swain SL, Wittmer S. Interferon gamma eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. *J Exp Med* 2000;192:117-22.
21. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol *Mycobacterium tuberculosis* infection, which is not compensated for by lymphotoxin. *J Immunol* 1999;162:3504-11.
22. Pfeffer K, Matsuyama T, Kundig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to *L. monocytogenes* infection. *Cell* 1993;73:457-67.
23. Havell EA. Evidence that tumor necrosis factor has an important role in antibacterial resistance. *J Immunol* 1989;143:2894-9.
24. Allendoerfer R, Deepe GS Jr. Blockade of endogenous TNF-alpha exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. *J Immunol* 1998;160:6072-82.
25. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* 1995;2:561-72.
26. Ehlers S, Benini J, Kutsch S, Endres R, Rietschel ET, Pfeffer K. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with *Mycobacterium avium*. *Infect Immun* 1999;67:3571-9.
27. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. *Infect Immun* 2001;69:1847-55.
28. Botha T, Ryffel B. Reactivation of latent tuberculosis infection in TNF-deficient mice. *J Immunol* 2003;171:3110-8.
29. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. *Cell* 1989;56:731-40.
30. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. *Gastroenterology* 2003;124:1774-85.
31. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. *J Exp Med* 2001;193:427-34.
32. Plitz T, Huffstadt U, Endres R, et al. The resistance against *Listeria monocytogenes* and the formation of germinal centers depend on a functional death domain of the 55 kDa tumor necrosis factor receptor. *Eur J Immunol* 1999;29:581-91.
33. Endres R, Luz A, Schulze H, et al. Listeriosis in p47(phox^{-/-}) and TRp55^{-/-} mice: protection despite absence of ROI and susceptibility despite presence of RNI. *Immunity* 1997;7:419-32.
34. Peschon JJ, Torrance DS, Stocking KL, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. *J Immunol* 1998;160:943-52.

35. Olleros ML, Guler R, Corazza N, et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to *Mycobacterium bovis* bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-alpha. *J Immunol* 2002;168:3394-401.
36. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. *Cytokine* 1995;7:251-9.
37. Luger A, Schmidt M, Luger N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. *Gastroenterology* 2001;121:1145-57.
38. Fratazzi C, Arbeit RD, Carini C, et al. Macrophage apoptosis in mycobacterial infections. *J Leukoc Biol* 1999;66:763-4.
39. Keane J, Remold HG, Kornfeld H. Virulent *Mycobacterium tuberculosis* strains evade apoptosis of infected alveolar macrophages. *J Immunol* 2000;164:2016-20.
40. Keane J, Shurtleff B, Kornfeld H. TNF-dependent BALB/c murine macrophage apoptosis following *Mycobacterium tuberculosis* infection inhibits bacillary growth in an IFN-gamma independent manner. *Tuberculosis* 2002;82:55-61.
41. Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. *J Exp Med* 1994;180:1499-509.
42. Stenger S, Mazzaccaro RJ, Uyemura K, et al. Differential effects of cytolytic T cell subsets on intracellular infection. *Science* 1997;276:1684-7.
43. Santucci MB, Amicosante M, Cicconi R, et al. *Mycobacterium tuberculosis*-induced apoptosis in monocytes/macrophages: early membrane modifications and intracellular mycobacterial viability. *J Infect Dis* 2000;181:1506-9.